Otmar Schaaf

Vienna, 1121, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.

Journal: Science translational medicine
Published: September 03, 2025

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.

Journal: Journal of medicinal chemistry
Published: July 25, 2025

Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.

Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.

Journal: Journal of medicinal chemistry
Published: July 14, 2023

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments.

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments.

Journal: ChemMedChem
Published: December 16, 2022

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.

Journal: Nature
Published: September 08, 2022

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.

Journal: Oncoimmunology
Published: June 27, 2022

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.

Journal: Molecular cancer therapeutics
Published: February 03, 2021

An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.

An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.

Journal: Cancer chemotherapy and pharmacology
Published: October 14, 2016

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Journal: Journal of medicinal chemistry
Published: February 26, 2016

A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.

A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.

Journal: Cancer chemotherapy and pharmacology
Published: December 18, 2015

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.

Journal: Molecular cancer therapeutics
Published: July 23, 2015

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

Journal: Molecular cancer therapeutics
Published: July 01, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026